Company Filing History:

9 out of 1,454

Sanofi

Years Active: 1993-2012

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8318696 - Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative (2012-11-27),

2. 7803811 - 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them (2010-09-28),

3. 7622488 - Use of a pyrazole derivative for preparing medicines useful for treating renal diseases (2009-11-24),

4. 7553845 - Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives (2009-06-30),

5. 7468368 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof (2008-12-23),

6. 7442708 - 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same (2008-10-28),

7. 7294628 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof (2007-11-13),

8. 6844329 - Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative (2005-01-18),

9. 6235793 - Use of agonists of adrenergic &bgr;-3 receptors for preparing wound-healing medicines (2001-05-22),

10. 6057318 - Heterocyclic derivatives, process for their preparation and their (2000-05-02),

11. 5891894 - Heterocyclic derivatives process for their preparation and their (1999-04-06),

12. 5891893 - Heterocyclic derivatives, process for their preparation and their (1999-04-06),

13. 5780468 - Heterocyclic derivatives, process for their preparation and their (1998-07-14),

14. 5607952 - Substituted 4-phenylthiazole derivatives, process for their preparation (1997-03-04),

15. 5576328 - Method for the secondary prevention of ischemic events (1996-11-19),

Title: Jean-Marc Herbert: A Pioneer in Pharmaceutical Innovations

Introduction

Jean-Marc Herbert, based in Tournefeuille, France, is an influential figure in the field of pharmaceutical innovations. With a portfolio encompassing 19 patents, he has demonstrated a strong commitment to advancing medical science through his groundbreaking inventions.

Latest Patents

Among his impressive recent contributions are several noteworthy patents. The first, titled "Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative," addresses novel synthetic polysaccharides that exhibit antithrombotic properties. This innovation includes a unique process utilizing avidin or streptavidin, allowing for the neutralization of these polysaccharides, marking a significant advancement in therapeutic options.

Another significant patent, "1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them," involves the creation of new indolizine derivatives that act as inhibitors of fibroblast growth factors. This patent not only covers the synthesis of these compounds but also their incorporation into pharmaceutical compositions and methods of treatment, which could hold promise for a variety of medical applications.

Career Highlights

Jean-Marc Herbert's career includes significant tenures at prominent companies such as Sanofi and Sanofi-Aventis, where he contributed to various innovative projects that pushed the boundaries of pharmaceutical research. His work at these institutions has solidified his reputation as a leading inventor in his field.

Collaborations

Throughout his career, Herbert has collaborated with notable individuals such as Alain Badorc and Andre Bernat. These partnerships have fostered a rich environment for innovation, allowing for the exchange of ideas that have further driven advancements in the biotechnology sector.

Conclusion

In summary, Jean-Marc Herbert's dedication to innovation in pharmaceuticals is evident through his extensive patent portfolio and impactful collaborations. His work continues to contribute to the advancement of medical science, providing new avenues for treatment and improving patient outcomes globally.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com